The company collaborates with clients to enhance their drug discovery programs, offering expertise in accelerating programs from hit-to-lead through to lead optimization. With a team of experienced biotech professionals, SYNthesis Med Chem can contribute to internal programs or independently run discovery efforts. They prioritize flexibility and cost effectiveness, aiming to provide scalable services to their clients. Additionally, SYNthesis Med Chem offers a library of kinase inhibitors and small molecule inhibitors for drug-discovery research, as well as molecular modeling solutions for protein interaction analysis. Based in Parkville, Australia, the company was acquired by SYNthesis on September 21, 2020.